BC Week In Review | Apr 11, 2011
Company News

Inspire, Merck deal

Merck will acquire ophthalmic company Inspire for $5 per share, or about $430 million in cash. The price is a 26% premium to Inspire's close of $3.98 on April 4, the day before the deal...
BC Extra | Apr 6, 2011
Company News

Merck to acquire Inspire

Merck & Co. Inc. (NYSE:MRK) will acquire ophthalmic company Inspire Pharmaceuticals Inc. (NASDAQ:ISPH) for $5 per share, or about $430 million in cash. The price is a 26% premium to Inspire's Monday close of $3.98,...
BC Week In Review | Feb 21, 2011
Company News

Inspire ophthalmic news

Inspire will reduce headcount by 65 (27%) to 175 and will discontinue its pulmonary program, including cystic fibrosis candidate denufosol to focus on its eye care business. In January, the second-generation P2Y2 receptor agonist missed...
BC Extra | Feb 18, 2011
Company News

Inspire cutting 27%, dropping denufosol

Inspire Pharmaceuticals Inc. (NASDAQ:ISPH) will reduce its headcount by 65 (27%) and discontinue its pulmonary program, including cystic fibrosis (CF) candidate denufosol. In January , the second-generation P2Y2 receptor agonist missed the primary endpoint in the...
BC Extra | Jan 4, 2011
Top Story

Inspire misses CF endpoint

Inspire Pharmaceuticals Inc. (NASDAQ:ISPH) fell $4.93 (59%) to $3.47 on Monday after denufosol missed the primary endpoint in the Phase III TIGER-2 trial to treat cystic fibrosis. The second-generation P2Y2 receptor agonist did not significantly...
BC Extra | Aug 5, 2009
Top Story

Inspire raises $100 million

Inspire Pharmaceuticals Inc. (NASDAQ:ISPH) raised $100 million through the sale of 22.2 million shares at $4.50 in a bumped-up follow-on underwritten by Deutsche Bank. Inspire proposed to raise up to $80 million late Tuesday, when...
BC Extra | Aug 5, 2009
Financial News

Inspire proposes follow-on

Inspire Pharmaceuticals Inc. (NASDAQ:ISPH) proposed late Tuesday to raise $80 million in a follow-on underwritten by Deutsche Bank. Inspire promotes AzaSite for bacterial conjunctivitis and co-promotes Elestat epinastine for allergic conjunctivitis. It also receives royalties...
BC Week In Review | Mar 16, 2009
Company News

Inspire ophthalmic, pulmonary news

Inspire will restructure and reduce headcount by 20 (8%) to 230, with cuts in preclinical research to focus on late stage clinical and marketed programs. The company's marketed products include AzaSite for bacterial conjunctivitis, Elestat...
BC Extra | Apr 24, 2008
Clinical News

Inspire discontinuing epinastine

Inspire (NASDAQ:ISPH) discontinued development of epinastine after the intranasal antihistamine missed the primary endpoint of a statistically significant change vs. placebo in baseline total nasal symptom score (TNSS) in a Phase III trial to treat...
BC Extra | Jul 19, 2007
Financial News

Inspire raises $75 million

ISPH raised $75 million through a private placement of 140,186 convertible preferred shares sold to Warburg Pincus . The preferred shares convert into about 14 million common shares at $5.35, which is a 5% premium to...
Items per page:
1 - 10 of 17